Trial Profile
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Azintuxizumab-vedotin (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 17 Sep 2021 Results from NCT02099058, NCT02365662, NCT02462525 and NCT02565758 assessing Neutropenia, presented at the 2021 American College of Clinical Pharmacology Annual Meeting
- 22 Jan 2020 Results (data cut off: April 3, 2018) assessing the safety, pharmacokinetics, and preliminary activity of ABBV-838 in patients with relapsed and refractory (RR) MMpublished in the Clinical Cancer Research
- 01 Jun 2017 Status changed from active, no longer recruiting to discontinued.